BG 9928, an oral A1 adenosine antagonist, shows promise for patients with heart failure

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1601, 2007-01, pp. : 8-8

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The Safety of an Adenosine A 1 -Receptor Antagonist, Rolofylline, in Patients with Acute Heart Failure and Renal Impairment: Findings from PROTECT

By Teerlink John R.

Drug Safety, Vol. 35, Iss. 3, 2012-03 ,pp. : 233-244

Adis International

Access to resources Recommend Favorite

Rolofylline: a selective adenosine 1 receptor antagonist for the treatment of heart failure

By Slawsky Mara T Givertz Michael M

Expert Opinion on Pharmacotherapy, Vol. 10, Iss. 2, 2009-02 ,pp. : 311-322

Informa Healthcare

Access to resources Recommend Favorite

Tezosentan shows potential for treating heart failure

Inpharma, Vol. 1, Iss. 1282, 2001-01 ,pp. : 9-10

Adis International

Access to resources Recommend Favorite

A novel non-xanthine adenosine A 1 receptor antagonist

By Terai T. Kita Y. Kusunoki T. Shimazaki T. Ando T. Horiai H. Akahane A. Shiokawa Y. Yoshida K.

European Journal of Pharmacology, Vol. 279, Iss. 2, 1995-06 ,pp. : 217-225

Elsevier

Access to resources Recommend Favorite

Adenosine therapy: a new approach to chronic heart failure

By Kitakaze M. Hori M.

Expert Opinion on Investigational Drugs, Vol. 9, Iss. 11, 2000-11 ,pp. : 2519-2535

Informa Healthcare

Access to resources Recommend Favorite